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Magnitude of the issue
Under staging of locally advanced bladder urothelial 
cancer (BUC) is an important issue as far as it impacts the 
treatment and may hamper eventually the prognosis. It 
is particularly true for cT1 BUC as far as guidelines (1) 
provide also conservative treatment, which is indeed unfit 
to treat invasive cancer, leading to an impaired chance of 
surviving. Overall, under staging is not a rare phenomenon. 
It ranges up to 25% in specimen of second transurethral 
resection (2) and up to 50% in specimen of radical 
cystectomy (1,3) without significant improvement in the last 
decades. 
How to deal with under staging 
How may we overcome the issue? Basically, there is a 
consensus on performing always a restaging as indicated 
by guidelines (TUR) (1). About 10% of cT1 BUC 
harbour invasive cancer after a second TUR is performed, 
independently from operator experience and technicalities 
adopted during the first procedure (2). Contrast computed 
tomography (CT) scan and magnetic resonance (MR) 
are reliable tools for the detection of nodal or distant 
metastasis when muscle invasive or metastatic cancer is 
suspected (1). Indeed, MR is gaining an increasing role in 
the local staging of BUC. In 2018, the VI-RADS score has 
been implemented (4). VI-RADS is a five-point scoring 
system linked to likelihood of up staging to muscle invasive 
disease. A validation study showed promising results. Area 
under the receiver operating characteristic curve was 0.94, 
with a 95% CI of 0.9–0.98, whereas a VI-RADS score of 3 
or greater had a sensitivity of 87.1% (95% CI: 78–93%) and 
specificity of 96.5% (95% CI: 93–98%), respectively (5). 
Clinical predictive factors of up staging may be also useful. 
Hydronephrosis at clinical presentation or lymphovascular 
invasion on TUR specimen are significantly linked with 
upstaging (3,6) as well as variant urothelial histology 
(micropapillary, nested, plasmacytoid, sarcomatoid) and 
prostatic urethral involvement (7) and should be considered 
when assessing a cT1 BUC. 
Molecular staging and bladder cancer
Molecular staging is a relatively new approach, based on 
pattern of genes expression in specimen of BUC tumours, 
which may be encompassed in the general concept of 
the precision medicine. Up to date, basically, two main 
subtypes of BUC have been identified, luminal and basal, 
the latter associated with a worse prognosis (8,9). An 
alternative classification, based also on cell cycle alteration 
and markers of differentiation, includes the subsequent 
subtypes: urothelial-like (luminal), genomically unstable, 
basal-squamous, mesenchymal-like, and neuroendocrine-
like subtype with most of the tumours belonging to the 
first three categories (10). As a matter of fact, BUCs are 
characterized by a discrete heterogeneity (10). Therefore, 
specimen used for subtyping analyses may only express 
one of the patterns which compose the entire tumour. 
Maybe this is the reason why, so far, concerns have been 
raised about usefulness of molecular subtyping at the 
present point of our knowledge (8). Its clinical impact 
has been retrospectively tested in patients with BUC. 
Basal BUC seemed linked with a better response to 
neoadjuvant chemotherapy (11) whereas no association 
has been found between subtyping and radiation response 
in a population submitted to trimodal therapy for invasive 
BUC (12). The study of Lotan and colleagues is original 
as far as they investigated the link between upstaging after 
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radical cystectomy and molecular subtyping (13). They 
retrospectively reviewed a cohort of patients submitted 
to radical cystectomy without prior neoadjuvant therapy. 
Overall 206 patients with cT1–2 patients were included 
in their analysis. One hundred had luminal subtype 
cancer and 106 non luminal. Non luminal patients had a 
significantly higher risk of up staging to pT3–4 disease (47% 
versus 24%). Moreover, adding molecular subtyping to 
clinical staging increased the area under the curve of their 
predictive model from 0.67 to 0.72. Probably, those findings 
may be translated to the subgroup of cT1 stage patients 
(87 subjects had a cT1 stage BUC and 31 were up staged to 
pT2–4 disease), making them extremely interesting. 
Conclusions
Under staging of cT1 BUC is yet a relevant issue. It may 
occur frequently even using the best of our knowledge. The 
combination of different modalities may at least reduce 
significantly the likelihood of under staging, which may 
have catastrophic consequences, due to improper allocation 
of the patient to the wrong treatment. Molecular subtyping 
as well as VI-RAD score of a dedicated MRI, if confirmed 
in larger, prospective cohorts, may be the missing piece of 
the puzzle 
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